Pharmacokinetic (PK), Pharmacodynamic (PD), and Exposure-Response (E-R) Analysis of Pegcetacoplan in C3 Glomerulopathy (C3G) and Primary Immune-Complex Membranoproliferative Glomerulonephritis (pIC-MPGN) (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0679; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Conclusion At indicated doses for patients ≥12 years, pegcetacoplan provides consistent exposure, rapid, sustained complement inhibition, and clinically meaningful and safe proteinuria reduction. This supports a fixed-dose adult regimen of 1080 mg twice weekly and weight-adjusted adolescent regimen without adjustment for renal function or proteinuria."
PK/PD data • Complement-mediated Rare Disorders • Glomerulonephritis • Lupus Nephritis • Nephrology • Renal Disease
|
|
Ali Keshavarz; Priska Kaufmann; Eli Khankin; Joel Melnick; Derek Wachtel; Shiva Voruganti
|